ConductScience.org, home

Paper34355232

Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data.

Schoretsanitis G and 3 others. Schizophr Bull, 2022. Cited by 38 papers, by iCite.

Cite this record

ConductScience Library. Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data. Papers, record 34355232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34355232

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data.
PubMed
Journal
Schizophr Bull
PubMed
Year
2022
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
38
iCite
Relative citation ratio, by iCite
4.58
iCite
Revised in PubMed
2026-01-27
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Schoretsanitis GGeorgioshttps://orcid.org/0000-0002-3851-4117
2Kane JMJohn M
3Correll CUChristoph U
4Rubio JMJose M

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antipsychotic AgentsMajor topic
Medication AdherenceMajor topic
RecurrenceMajor topic
SchizophreniaMajor topic
Administration, Oral
Adult
Female
Humans
Male
Middle Aged
Proportional Hazards Models
Drug Monitoring

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in34964477Confounding of Antipsychotic Discontinuation Studies by Withdrawal-Related Relapse.https://conductscience.org/library/papers/34964477

Source PubMed

Download CSV of comments and corrections

References40

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130540353Factors Associated With Successful Medication Discontinuation After a Randomized Clinical Trial of Relapse Prevention in First-Episode Psychosis: A 10-Year Follow-up.JAMA Psychiatry2019https://conductscience.org/library/papers/30540353PubMed
229146020Clinical and demographic predictors of continuing remission or relapse following discontinuation of antipsychotic medication after a first episode of psychosis. A systematic review.Schizophr Res2018https://conductscience.org/library/papers/29146020PubMed
321920710Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication - a 10-year follow-up of the Northern Finland 1966 Birth Cohort study.Eur Psychiatry2013https://conductscience.org/library/papers/21920710PubMed
432828165Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis.Lancet Psychiatry2020https://conductscience.org/library/papers/32828165PubMed
532220153Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study.J Clin Psychiatry2020https://conductscience.org/library/papers/32220153PubMed
628277310Antipsychotic medication and remission of psychotic symptoms 10years after a first-episode psychosis.Schizophr Res2017https://conductscience.org/library/papers/28277310PubMed
723558429Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study.Am J Psychiatry2013https://conductscience.org/library/papers/23558429PubMed
823612934A 3-year retrospective cohort study of predictors of relapse in first-episode psychosis in Hong Kong.Aust N Z J Psychiatry2013https://conductscience.org/library/papers/23612934PubMed
926939910Altering the course of schizophrenia: progress and perspectives.Nat Rev Drug Discov2016https://conductscience.org/library/papers/26939910PubMed
1031866076Negative symptoms predict high relapse rates and both predict less favorable functional outcome in first episode psychosis, independent of treatment strategy.Schizophr Res2020https://conductscience.org/library/papers/31866076PubMed
1125066792Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study.Psychol Med2014https://conductscience.org/library/papers/25066792PubMed
1229856543What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?World Psychiatry2018https://conductscience.org/library/papers/29856543PubMed
136275811Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia.Arch Gen Psychiatry1982https://conductscience.org/library/papers/6275811PubMed
1423756298The evidence for illness progression after relapse in schizophrenia.Schizophr Res2013https://conductscience.org/library/papers/23756298PubMed
1531059621Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons.World Psychiatry2019https://conductscience.org/library/papers/31059621PubMed
1625562685Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.J Clin Psychiatry2015https://conductscience.org/library/papers/25562685PubMed
1726189570Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study.J Clin Pharmacol2016https://conductscience.org/library/papers/26189570PubMed
183192266920-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20).World Psychiatry2020https://conductscience.org/library/papers/31922669PubMed
1912892869Neuroleptic withdrawal in treatment-resistant patients with schizophrenia: tardive dyskinesia is not associated with supersensitive psychosis.Schizophr Res2003https://conductscience.org/library/papers/12892869PubMed
2026811679Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study.Neuropsychiatr Dis Treat2016https://conductscience.org/library/papers/26811679PubMed

See all 40 referencesDownload CSV of references

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 38 citations.

PMIDTitleJournalYearIn PapersSource
42847024Are Depot Antipsychotics Ever Self-Tapering? Exploring the Discontinuation of Long-Acting Injectable Psychosis Drugs and Those With Delayed Onset Through In Silico Modelling.Schizophr Bull Open2026https://conductscience.org/library/papers/42847024PubMed
41910757[Olanzapine long acting injectable in new application form-Hope for the absence of post-injection delirium/sedation syndromes].Nervenarzt2026https://conductscience.org/library/papers/41910757PubMed
41511922Community management: An effective model to reduce medication discontinuation rate in patients with schizophrenia.PLoS One2026https://conductscience.org/library/papers/41511922PubMed
41407750Helping people to discontinue antipsychotics: if, when and how.Schizophrenia (Heidelb)2025https://conductscience.org/library/papers/41407750PubMed
41057718The Use of Long-Acting Injectables for People with Schizophrenia: Consensus Panel Recommendations for Overcoming Barriers and Implementing Treatment.Neurol Ther2025https://conductscience.org/library/papers/41057718PubMed
41019822Treatment Patterns and Outcomes from OASIS: A Prospective Observational Study of Long-Acting Injectables in Schizophrenia.Neuropsychiatr Dis Treat2025https://conductscience.org/library/papers/41019822PubMed
40971553Not So Hasty: The Effect of Tapering Speed on Relapse May Still Be Important.Schizophr Bull2026https://conductscience.org/library/papers/40971553PubMed
40958797Optimizing long-acting injectable antipsychotic safety and care continuity through documentation best practices.Front Psychiatry2025https://conductscience.org/library/papers/40958797PubMed
40826949Long-acting injectable antipsychotics for patients with first-episode and early-phase schizophrenia: still not considered often enough.CNS Spectr2025https://conductscience.org/library/papers/40826949PubMed
39282238Using in silico methods to determine optimal tapering regimens for decanoate-based long-acting injectable psychosis drugs.Ther Adv Psychopharmacol2024https://conductscience.org/library/papers/39282238PubMed
38868633The pharmacological treatment of schizophrenia: How far have we come?PCN Rep2022https://conductscience.org/library/papers/38868633PubMed
38275523Rethinking Clozapine: Lights and Shadows of a Revolutionary Drug.Brain Sci2024https://conductscience.org/library/papers/38275523PubMed
38250810
The effects of antipsychotic discontinuation or maintenance on the process of recovery in remitted first-episode psychosis patients - A systematic review and meta-analysis of randomized controlled trials.
Eur Psychiatry2024https://conductscience.org/library/papers/38250810PubMed
37935711Symptomatic, functional and quality of life measures of remission in 194 outpatients with schizophrenia followed naturalistically in a 6-month, non-interventional study of aripiprazole once-monthly.Schizophrenia (Heidelb)2023https://conductscience.org/library/papers/37935711PubMed
37797288Does Slow and Steady Win the Race? Rates of Antipsychotic Discontinuation, Antipsychotic Dose, and Risk of Psychotic Relapse.Schizophr Bull2024https://conductscience.org/library/papers/37797288PubMed
37786804Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia.Ther Adv Psychopharmacol2023https://conductscience.org/library/papers/37786804PubMed
37719449Implementing gradual, hyperbolic tapering of long-acting injectable antipsychotics by prolonging the inter-dose interval: an in silico modelling study.Ther Adv Psychopharmacol2023https://conductscience.org/library/papers/37719449PubMed
36277256Chronic Use of Antipsychotics in Schizophrenia: Are We Asking the Right Question?Schizophr Bull Open2022https://conductscience.org/library/papers/36277256PubMed
35573364Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis.Front Psychiatry2022https://conductscience.org/library/papers/35573364PubMed
35543395Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries.Epidemiol Psychiatr Sci2022https://conductscience.org/library/papers/35543395PubMed

See all 23 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34355232

GET https://conductscience.org/api/papers/v1/34355232/references?page=2